Related Experiment Videos
Diagnosis and management of chronic neutropenia during childhood
1Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, USA.
Insights
Neutropenia diagnosis often relies on clinical history and bone marrow, not extensive labs. While many patients live normally, severe cases benefit from treatments like rhG-CSF, which is safe long-term.
Area of Science:
- Hematology
- Pediatric Hematology
- Clinical Immunology
Background:
- Neutropenia, a condition characterized by low neutrophil counts, requires careful diagnostic evaluation.
- Clinical history and physical examination are crucial for guiding the diagnostic approach.
- Bone marrow morphology aids in classifying and managing chronic neutropenia, particularly in children.
Purpose of the Study:
- To outline an effective diagnostic and management strategy for neutropenia.
- To emphasize the role of clinical assessment over extensive laboratory testing in many cases.
- To discuss the utility and safety of rhG-CSF in managing severe neutropenia.
Main Methods:
- Evaluation of diagnostic approaches based on clinical history and physical examination.
- Assessment of bone marrow morphology for classification and management.
- Review of treatment strategies, including the use of recombinant human granulocyte-colony stimulating factor (rhG-CSF).
Main Results:
- Most children with chronic neutropenia can be classified and managed using history and bone marrow morphology.
- Many patients with chronic neutropenia maintain a normal lifestyle with minimal intervention.
- Recombinant human granulocyte-colony stimulating factor (rhG-CSF) has significantly improved outcomes for severe neutropenia, with long-term data suggesting safety.
Conclusions:
- Diagnostic evaluation for neutropenia can often be guided by clinical assessment, reducing the need for extensive laboratory workups.
- While many patients require minimal intervention, those with severe or recurrent infections necessitate careful monitoring and treatment.
- rhG-CSF is a valuable, albeit expensive, therapeutic option for severe neutropenia, and its chronic administration appears safe.
Abstract:
The approach to the diagnostic evaluation of a patient with neutropenia can be guided largely by clinical history and physical examination and does not always require an extensive laboratory evaluation. Based on the history and bone marrow morphology, most children with chronic neutropenia can be classified and managed. Most patients with chronic neutropenia are free of infections and are able to maintain a normal lifestyle with no or minimal medical intervention. On the other hand, for patients with recurrent or severe infections, careful follow-up and institution of treatment are mandatory. The Food and Drug Administration has approved the use of rhG-CSF in patients with chronic neutropenia. As mentioned previously, the use of colony-stimulating factors has dramatically improved the outcome for many patients with the more severe neutropenia; however, this cytokine is expensive, so treatment should be reserved for more severely affected patients and not given just because the ANC is low. Although concerns exist regarding leukemogenic effects or eventual loss of the progenitor cell compartment driven by the continuous stimulation of rhG-CSF, at this moment, the long-term data available suggest that the chronic administration of rhG-CSF is safe.